Head-to-head evidence
APVO436 vs MGD024
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 x CD3 · full Acute Myeloid Leukemia pipeline
APVO436
Developed by Aptevo Therapeutics
NCT03647800 · Phase 1 · status unknown
This is an open-label, single-arm, dose-escalation and dose-expansion study with no control group and no blinding, so it cannot demonstrate a treatment effect on its own. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
These results cover the monotherapy dose-escalation cohort only; combination-therapy expansion cohorts added later are not included. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT06634394 (registry estimate)
MGD024
Developed by MacroGenics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APVO436's landscape · MGD024's landscape